The social network for physicians recently went public in an upsized IPO that valued the company at about $4.6 billion. With many physicians already on the platform, chief strategy officer Dr. Nate Gross shared the company’s plans for future growth.
Starting on Saturday, the exchange is instituting a discount on its annual listing fee for pre-revenue companies, capping it at $100,000 per year over three years. While the policy applies across industries, it is an effort to draw biotech companies that would usually list on the Nasdaq.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
An NYSE ad that debuted this week includes some screen time for Evolent Health CEO Frank Williams
Telemedicine service provider Teladoc priced its IPO Tuesday night at $19, well above the previously announced range of $15-$17, then shares soared Wednesday morning.
Merck (NYSE:MRK) has forged a deal with a biopharmaceutical company for its phase 3 platinum-resistant ovarian cancer treatment and nonsmall cell lung cancer in mid-stage development in a deal valued at up to $1 billion. Under the terms of the deal, Merck, through a subsidiary, will get worldwide rights to develop and commercialize vintafolide for […]